106 related articles for article (PubMed ID: 15333188)
1. Evidence for the clinical use of tumour markers.
Duffy MJ
Ann Clin Biochem; 2004 Sep; 41(Pt 5):370-7. PubMed ID: 15333188
[TBL] [Abstract][Full Text] [Related]
2. How to integrate serum tumor markers into clinical oncologic practice.
van Dalen A
Nutrition; 1995; 11(5 Suppl):489-91. PubMed ID: 8748205
[TBL] [Abstract][Full Text] [Related]
3. Use of common seric tumor markers in patients with solid cancers.
Gara S; Boussen H; Ghanem A; Guemira F
Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
[TBL] [Abstract][Full Text] [Related]
4. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
Kumar Y; Tapuria N; Kirmani N; Davidson BR
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer and neoadjuvant therapy: any predictive marker?
Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
[TBL] [Abstract][Full Text] [Related]
6. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of tumour markers.
Lai LC; Cheong SK; Goh KL; Leong CF; Loh CS; Lopez JB; Nawawi H; Sivanesaratnam V; Subramaniam R;
Malays J Pathol; 2003 Dec; 25(2):83-105. PubMed ID: 16196365
[TBL] [Abstract][Full Text] [Related]
8. Serum tumor markers in patients with breast cancer.
Lumachi F; Basso SM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):921-31. PubMed ID: 15485325
[TBL] [Abstract][Full Text] [Related]
9. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
11. Role of tumor markers in patients with solid cancers: A critical review.
Duffy MJ
Eur J Intern Med; 2007 May; 18(3):175-84. PubMed ID: 17449388
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
13. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
14. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
Margel D; Tal R; Baniel J
J Urol; 2007 Dec; 178(6):2297-300; discussion 2300-1. PubMed ID: 17936837
[TBL] [Abstract][Full Text] [Related]
15. Serum tumour markers in clinical practice. Some general aspects.
Kvinnsland S
Scand J Clin Lab Invest Suppl; 1991; 206():6-11. PubMed ID: 1947761
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial designs for predictive marker validation in cancer treatment trials.
Sargent DJ; Conley BA; Allegra C; Collette L
J Clin Oncol; 2005 Mar; 23(9):2020-7. PubMed ID: 15774793
[TBL] [Abstract][Full Text] [Related]
17. Use of tumour markers in cancer diagnosis and treatment.
Higgins C
Nurs Times; 1996 Apr 17-23; 92(16):36-7. PubMed ID: 8710591
[TBL] [Abstract][Full Text] [Related]
18. The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours.
Venkitaraman R; Johnson B; Huddart RA; Parker CC; Horwich A; Dearnaley DP
BJU Int; 2007 Jul; 100(1):30-2. PubMed ID: 17552950
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of plasma D-dimer levels in patients with colorectal cancer.
Kilic M; Yoldas O; Keskek M; Ertan T; Tez M; Gocmen E; Koc M
Colorectal Dis; 2008 Mar; 10(3):238-41. PubMed ID: 17868411
[TBL] [Abstract][Full Text] [Related]
20. Tumor markers in staging and prognosis of colorectal carcinoma.
Levy M; Visokai V; Lipska L; Topolcan O
Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
